HC Wainwright Reaffirms Buy Rating for Immune Design (IMDZ)

HC Wainwright reiterated their buy rating on shares of Immune Design (NASDAQ:IMDZ) in a report released on Monday. They currently have a $8.00 price target on the biotechnology company’s stock.

“Valuation and risks to price target achievement. We reiterate our Buy rating and $7.75 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. We believe upside potential exists as the company explores additional tumor indications for G100, as well as potential Immune Design Corp. December 3, 2018 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2contribution from pipeline development.”,” the firm’s analyst commented.

IMDZ has been the subject of several other research reports. Zacks Investment Research raised shares of Immune Design from a hold rating to a buy rating and set a $1.75 price objective for the company in a research note on Friday, November 30th. Leerink Swann cut shares of Immune Design from an outperform rating to a market perform rating in a research note on Friday, October 12th. Finally, Royal Bank of Canada reaffirmed an outperform rating and set a $11.00 price objective on shares of Immune Design in a research note on Friday, October 12th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Immune Design has a consensus rating of Buy and an average price target of $7.19.

Shares of NASDAQ:IMDZ opened at $1.76 on Monday. The company has a market cap of $77.06 million, a P/E ratio of -1.01 and a beta of 2.56. Immune Design has a 12 month low of $1.25 and a 12 month high of $5.05.

Immune Design (NASDAQ:IMDZ) last issued its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.03. The company had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.75 million. Immune Design had a negative net margin of 2,409.84% and a negative return on equity of 43.44%. As a group, equities analysts forecast that Immune Design will post -1.14 EPS for the current year.

In other Immune Design news, major shareholder Bvf Partners L. P/Il sold 902,000 shares of Immune Design stock in a transaction that occurred on Tuesday, December 4th. The shares were sold at an average price of $1.83, for a total transaction of $1,650,660.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 18.10% of the company’s stock.

A number of institutional investors have recently made changes to their positions in IMDZ. Alps Advisors Inc. bought a new stake in Immune Design during the second quarter valued at approximately $318,000. BlackRock Inc. lifted its position in Immune Design by 10.6% during the second quarter. BlackRock Inc. now owns 2,121,271 shares of the biotechnology company’s stock valued at $9,651,000 after purchasing an additional 204,171 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Immune Design by 132.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 447,026 shares of the biotechnology company’s stock worth $2,034,000 after acquiring an additional 254,696 shares during the last quarter. Tiverton Asset Management LLC bought a new stake in shares of Immune Design in the 2nd quarter worth approximately $176,000. Finally, Portolan Capital Management LLC bought a new stake in shares of Immune Design in the 2nd quarter worth approximately $2,024,000. Institutional investors and hedge funds own 46.27% of the company’s stock.

About Immune Design

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

Featured Story: Growth Stocks, What They Are, What They Are Not

Analyst Recommendations for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply